A Dutch bankruptcy has shown how thin Britain's medical cannabis supply line is
Some British children with severe epilepsy take an oil made from Bedrolite, a cannabis variety grown by one company in the Netherlands. That company is bankrupt, and what happens next is being decided in The Hague.
When Bedrocan went bankrupt in the Netherlands last month, most of the coverage treated it as a Dutch story. The grower had lost its state contract, and a delayed reform law left it without a market. All 69 staff at Bedrocan Nederland were dismissed.
For a small number of families in Britain it is closer to home. Bedrolite is a CBD-rich cannabis variety, made into an oil that some British children with treatment-resistant epilepsy are prescribed, and Bedrocan is the only company that grows it. As a company spokesperson put it in October, "Bedrolite is currently only cultivated in the Netherlands". The variety now sits in the Dutch bankruptcy estate.
What the Dutch government has said
On 6 November the Dutch health minister, Sophie Hermans, wrote to the Tweede Kamer about the collapse (the letter, in Dutch). According to reports of the letter by cannabisindustrie.nl and Business of Cannabis, harvests came in lower than expected, in some cases by more than half, so there is no spare Bedrolite. The cabinet is looking at whether the UK can be supplied for somewhat longer. It estimates that Dutch stocks of Bedrolite will run out in early Q3 2027.
British supply may run out sooner. On 23 October Target Healthcare, the UK manufacturer, said it had enough Bedrolite material for about six months.
Nothing in the Dutch plan for after that guarantees Bedrolite. The Bureau Medicinale Cannabis intends to publish a European tender for a new supplier in December, choose one in May 2027 and take delivery from September 2027. Once current varieties run out, patients will have to move to another product.
A restart could still keep the variety going. The Erkelens family, who founded Bedrocan, say they are pursuing one, but the trustees have not named the bidder. The curators have a draft purchase agreement that is not yet signed, and Business of Cannabis reports that the deal still needs the supervisory judge's approval.
A British problem
Britain made cannabis-based medicines legal for specialist doctors to prescribe in November 2018. Eight years on, a group of patients whose treatment works depends on one grower in another country, and on that country's procurement rules. Some of the responsibility for that lies in London.
The UK government's only public word so far, according to Leafie, came when health minister James Frith told the Liberal Democrat MP Anna Sabine that the British Embassy in The Hague was in contact with the Dutch health ministry. No plan has been published for what happens when the oil runs out.
Joanne Griffiths of End Our Pain says her son Ben's seizures fell by more than 90% after he started Bedrolite and Bedica in 2019, and that an interruption to his Bedica treatment during an illness in 2023 was linked to a life-threatening deterioration. Matt Hughes of the Medcan Family Foundation calls the situation "an immediate risk to life for children and young people who rely on Bedrolite".
Those are parents' accounts, and they explain why switching product is a serious step for these children. When one product has brought a child's seizures under control, changing it carries clinical risk. It needs time, and a doctor watching closely.
Volteface has written before that consistent supply is one of the weak points of Britain's legal cannabis market. Bedrolite is a clear example. The government should say publicly what it has asked the Dutch for, whether a British supplier could grow or import an equivalent, and how these patients will be moved safely if Bedrolite does stop. The Tweede Kamer holds a committee debate on the collapse on 26 November. The UK government should not wait for that debate to set out its own plan.
The other side
The Dutch state has a reasonable case. Hermans told parliament that the state declined to support Bedrocan's finances because of the risk that "the State would pay for unusable medicinal cannabis", and the cabinet refused support after negative advice from the State Attorney. The Dutch programme exists for Dutch patients, about 7,000 of them on Bedrocan products, and Dutch taxpayers are not obliged to underwrite British prescriptions.
On the British side, almost all cannabis prescriptions are written privately; Volteface has reported that NHS prescriptions remain rare. It is fair to argue that securing supply is the job of the companies that import and sell these products, and of the prescribers who chose them, rather than of ministers. Bedrolite is also an unlicensed medicine. A regulator could reasonably say that the answer to a supply shock is a careful switch under medical supervision, rather than diplomacy to keep one brand on the market.
Sources
- Business of Cannabis: Bedrocan could be revived under new entity as Dutch minister tells parliament UK supply is under investigation
- cannabisindustrie.nl: Wijziging Opiumwet uitgesteld, geen steun voor Bedrocan
- Dutch Ministry of Health, Welfare and Sport: Letter from the Minister of Health to the Tweede Kamer on medicinal cannabis, 6 November 2026 (in Dutch; copy hosted by cannabisindustrie.nl)
- MMJ Daily: Curators' report sheds light on the final weeks of Dutch medical cannabis grower Bedrocan
- MMJ Daily: Bedrolite stays in Bedrocan's Dutch bankruptcy estate as Denmark keeps growing the other varieties
- Leafie: British families face uncertain future while cannabis medicine sits in storage
- cannabisindustrie.nl: Oprichter Bedrocan: Kamer selectief geïnformeerd
- cannabisindustrie.nl: Exportplan Bedrocan
- legislation.gov.uk: The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018
- faillissementsdossier.nl: First public bankruptcy report, Bedrocan Nederland B.V.
The week in drugs and drug policy, in one email.
The newsletter opens soon. Follow the RSS feed in the meantime.

